Business
Cabaletta Bio to Present at the American Society of Gene and Cell Therapy 26th Annual Meeting
PHILADELPHIA, May 02, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching
About this update from Cabaletta Bio, Inc.
[{"type":"text","content":"PHILADELPHIA, May 02, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that Samik Basu, M.D., Chief Scientific Officer at Cabaletta Bio, will deliver an invited, oral presentation titled “CD 19 CAR T-cells for SLE” as part of the session titled “Immune Effector Cells: 2023 and Beyond!” on Tuesday, May 16, 2023, at 11:05 a.m. PT at the upcoming American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting, which is being held at the Los Angeles Convention Center in Los Angeles, CA from May 16-20, 2023. In addition, new preclinical data for CABA-201, a 4-1BB-containing fully human CD19-CAR T cell investigational therapy, and updated clinical and translational data from the ongoing DesCAARTes™ trial for DSG3-CAART in adults with mucosal-dominant pemphigus vulgaris (mPV) will be presented in poster presentations. Details of the poster presentations are as follows: Title: Preclinical Specificity and Activity of CABA-201, a Fully Human 4-1BB Containing CD19 CAR T Therapy for Treatment-Resistant Autoimmune DiseaseAbstract Number: 1418Date and Time: Friday, May 19, 2023, 12:00 p.m. – 2:00 p.m. PTPresenter: Jinmin Lee, Ph.D., Associate Director, Preclinical Research and Jason Peng, Ph.D., Senior Scientist at Cabaletta Bio Title: Correlative Findings Following DSG3-CAART Infusion with and without Combination Preconditioning Therapy in Patients with Pemphigus Vulgaris (DesCAARTes™ Study)Abstract Number: 1138Date and Time: Thursday, May 18, 2023, 12:00 p.m. – 2:00 p.m. PTPresenter: Jenell Volkov, Ph.D., Director, Translational Medicine and Daniel Nunez, Ph.D., Associate Director, Computational Biology at Cabaletta Bio Additional information, including the accepted abstracts, can be accessed on the ASGCT website. Presentation materials will be made available on the Posters & Publications section of the Company’s website following the event. About CAR T Cell TherapyChimeric Antigen Receptor (CAR) T cells are designed to achieve transient depletion of all B cells following a single treatment by using T cells engineered to express an antibody fragment that recognizes a B cell receptor expressed on the surface of all B cells, which is designed to allow for...